What is Ranitidine for? Instructions for use, price, reviews, indications for use

Ranitidine is a representative of Ukrainian antiulcer drugs of the second generation. It belongs to H2-histamine receptor antagonists, and helps patients in the fight against peptic ulcers and gastroesophageal reflux disease, in which the production of hydrochloric acid in the stomach increases. The drug has an antisecretory effect.

The drug enters the parietal cells and interacts with the cell membranes of the gastric mucosa through competitive inhibition of histamine-sensitive receptors. As a result, basal and stimulated secretion of hydrochloric acid decreases. There is a decrease in the volume of gastric juice, which is produced during food loads and the action of hormones: gastrin, histamine and pentagastrin on the gastric walls. The drug increases the pH value of the contents in the stomach and reduces the activity of an enzyme called pepsin.

Compound

The film-coated tablet contains 150/300 mg ranitidine hydrochloride .
Excipients: silicon dioxide (colloid), MCC (type 12), copovidone, Mg stearate. Film shell components (white Opadry AMB OY-B28920): soy lecithin, talc, xanthan gum, titanium dioxide, polyvinyl alcohol .

Solution for injection (1 ml) contains 0.025 grams of ranitidine hydrochloride .

pharmachologic effect

Ranitidine Akos is an antiulcer drug, the active substance of which belongs to the group of histamine H2 receptor antagonists. The principle of action is based on blocking H2 receptors in parietal cells located in the gastric mucosa, as well as inhibiting the production of hydrochloric acid . Under the influence of the active substance, the volume of total secretion decreases, suppressing the activity of pepsin in gastric juice .

Thanks to the antisecretory effect of Ranitidine, it is possible to create favorable conditions for the healing of ulcerative lesions in the digestive tract (stomach, duodenum). The active substance is capable of exerting a protective effect by enhancing reparative processes, increasing the secretion of special mucous substances, and improving microcirculation.

Pharmacological properties of the drug Ranitidine

Ranitidine is an antisecretory agent, an H2-histamine receptor antagonist. The mechanism of action is due to competitive reversible inhibition of the action of histamine on H2 receptors of the membranes of parietal cells of the gastric mucosa. Suppresses basal and stimulated secretion of hydrochloric acid, caused, in particular, by baroreceptor irritation (gastric distension), food load, the action of hormones and biogenic stimulants (gastrin, histamine, acetylcholine, pentagastrin, caffeine). Reduces pepsin activity. Strengthens the protective mechanisms of the gastric mucosa and promotes the healing of its damage caused by acid exposure, by reducing gastric secretion and increasing the formation of gastric mucus, the content of glycoproteins in it, stimulating the secretion of bicarbonate ions by the gastric mucosa, endogenous synthesis of prostaglandins in it and regeneration processes. The duration of action for a single oral dose is 12 hours. When taken orally, the bioavailability of ranitidine is approximately 50%. The maximum concentration in blood plasma is achieved 2–3 hours after oral administration. With intramuscular administration, the maximum concentration in blood plasma is achieved in the first 15 minutes after administration. Ranitidine is excreted primarily in the urine. Partially metabolized in the liver. The half-life is 2–3 hours. About 93% of the dose administered intravenously and 60–70% of the dose taken orally are excreted in the urine, the rest in feces. Approximately 70% of ranitidine administered intravenously and about 35% taken orally are excreted unchanged in the urine. Penetrates through the placenta and into breast milk.

Pharmacodynamics and pharmacokinetics

The active substance ranitidine is absorbed quite quickly from the lumen of the digestive tract. Food has no effect on the degree of absorption. Bioavailability reaches 50%. Peak concentrations are recorded within 2-3 hours after oral administration. 15% bound to plasma proteins. Partial metabolism takes place in the hepatic system with the formation of ranitidine S-oxide and desmethylranitidine .

The drug is characterized by a “first pass” effect through the hepatic system. The condition of the liver affects the extent and rate of elimination. After oral administration, the half-life is 2.5 hours, and with a creatinine clearance of 20-30 ml/min, this figure increases to 8-9 hours.

A small amount is excreted in the feces, the main part is excreted unchanged through the renal system. The active component does not pass the blood-brain barrier well, but penetrates the placenta well. Ranitidine is released during lactation.

Indications for use of Ranitidine

Ranitidine tablets - what do they help with? The main area of application of the drug is gastroenterology .

Ranitidine Akos - what does it help with? The drug is prescribed for the treatment of various pathologies of the digestive system, and can also be used for prophylactic purposes.

Indications for use of Ranitidine Acri

symptomatic ulcerative lesions of the digestive tract;
peptic ulcer of the digestive system (stomach, duodenum);
Zollinger-Ellison syndrome;
prevention of aspiration of gastric juice during surgical interventions with the introduction of anesthesia;
prevention of the development of “stress” ulcers;
reflux esophagitis;
erosive esophagitis;
prevention of the development of ulcerative lesions of the gastrointestinal tract after surgical interventions;
prevention of recurrent bleeding from the upper digestive tract.

Indications for use of Ranitidine Sopharma are similar.

Ranitidine

Ranitidine

(lat.
ranitidine
) - an antiulcer drug, a blocker of histamine H2 receptors. Historically, it is the second (after cimetidine) antisecretory drug that suppresses acid production in the stomach. It is currently considered relatively old, has more side effects than modern drugs and is less effective than famotidine and proton pump inhibitors. In the fall of 2021, a number of drugs containing ranitidine were banned for use or approval for their use in clinical practice was temporarily suspended by regulators in many countries due to the presence or suspicion of the presence (the latter motivated by unsatisfactory testing of the drug for this ingredient) of potential carcinogen - N-nitrosodimethylamine.

The FDA, in its release dated April 1, 2021, required that all drugs containing ranitidine be removed from use and sale in US pharmacies due to the fact that when stored at temperatures above room temperature, drugs containing ranitidine may increase the amount of N-nitrosodimethylamine in some of them .

Ranitidine is a chemical compound

N-[2-[[5-(Dimethylaminomethyl)furfuryl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine hydrochloride. Empirical formula: C13H22N4O3S.

Ranitidine is a drug

Ranitidine is the international nonproprietary name (INN) of the drug. According to the pharmacological index, it belongs to the group “II generation H2-histamine receptor blockers”. According to ATC, it belongs to the group “H2-histamine receptor blockers” and has the code A02BA02.

Pharmacodynamics of ranitidine

Ranitidine is a blocker of histamine H2 receptors on parietal cells of the gastric mucosa. Reduces basal and stimulated secretion of hydrochloric acid caused by irritation of baroreceptors, food load, the action of hormones and biogenic stimulants (gastrin, histamine, pentagastrin). Ranitidine reduces the volume of gastric juice and the content of hydrochloric acid in it, reduces the acidity of the stomach, which leads to a decrease in pepsin activity. The duration of action of ranitidine after a single dose is up to 12 hours.

Pharmacokinetics of ranitidine

When taken orally, the bioavailability of ranitidine is 50%. Plasma protein binding does not exceed 15%. Partially metabolized in the liver. Maximum concentrations of ranitidine in plasma are achieved 2 hours after taking film-coated tablets, 1 hour after taking effervescent tablets and range from 36 to 94 ng/ml. The half-life is 2-3 hours. About 30% of the administered dose of ranitidine is excreted unchanged in the urine, and a small amount is excreted in the feces. Penetrates through the placenta. Excreted in breast milk.

Professional medical work covering the treatment of gastrointestinal diseases with ranitidine

Gorbakov V.V., Makarov Yu.S., Golochalova T.V. Comparative characteristics of antisecretory drugs of various groups according to daily pH monitoring // Attending physician. 2001. – No. 5–6.
Yakovenko E.P. Zantac in the treatment of acid-related diseases. RGMU, Federal Gastroenterological Center, Moscow.
Makhakova G.Ch., Dicheva D.T., Odintsova T.A. and others. Comparative characteristics of acid-suppressing drugs by conducting pharmacological tests with intragastric daily pH-metry // Attending physician. – 1999. – No. 6. – P. 24–26.

On the website gastroscan.ru in the literature catalog there is a section “H2-blockers”, containing articles devoted to the treatment of diseases of the gastrointestinal tract using H2-blockers of histamine receptors, including the use of ranitidine.

Indications for use of ranitidine

treatment and prevention of exacerbations of gastric and duodenal ulcers;
stomach and duodenal ulcers associated with taking NSAIDs;
reflux esophagitis, erosive esophagitis;
Zollinger-Ellison syndrome;
treatment and prevention of postoperative, “stress” stomach ulcers;
prevention of recurrent bleeding from the upper gastrointestinal tract;
prevention of aspiration of gastric juice during operations under anesthesia (Mendelssohn syndrome).

Method of administration of ranitidine and dose

Peptic ulcer of the stomach and duodenum. To treat exacerbations, ranitidine is prescribed 150 mg 2 times a day (morning and evening) or 300 mg at night. If necessary, 300 mg 2 times a day. The duration of treatment is 4-8 weeks. To prevent exacerbations, 150 mg is prescribed at night.
Ulcers associated with NSAIDs. Prescribe 150 mg of ranitidine 2 times a day or 300 mg at night for 8-12 weeks. Prevention of ulcer formation when taking NSAIDs - 150 mg 2 times a day.
Postoperative ulcers. Prescribe 150 mg of ranitidine 2 times a day for 4-8 weeks.
Gastroesophageal reflux disease. Prescribe 150 mg 2 times a day or 300 mg at night. If necessary, the dose can be increased to 150 mg 4 times a day. The course of treatment is 8-12 weeks.
Zollinger-Ellison syndrome. The initial dose is 150 mg ranitidine 3 times a day, the dose can be increased if necessary.
Prevention of recurrent bleeding. 150 mg 2 times a day.
Prevention of the development of Mendelssohn's syndrome. Ranitidine is prescribed at a dose of 150 mg 2 hours before anesthesia, and also, preferably 150 mg the night before.

Ranitidine is taken regardless of meals, without chewing, with a small amount of liquid.
Effervescent tablets are dissolved in a glass of water and drunk after complete dissolution.

For patients with renal failure with creatinine clearance less than 50 ml/min, the recommended dose is 150 mg of ranitidine per day.

Experience with the use of ranitidine in the treatment of functional heartburn

The updated American Gastroenterological Association functional heartburn guidelines (2020) present results from treating patients with functional heartburn with ranitidine 150 mg daily. It is noted that ranitidine has an analgesic effect by reducing the sensitivity of esophageal chemoreceptors to acid perfusion (Fass R., Zerbib F., Gyawali CP).

Precautions when using ranitidine

It is undesirable to abruptly stop taking ranitidine due to the risk of relapse of peptic ulcer disease.
Ranitidine should be used with caution in patients with impaired renal and hepatic function.
Before starting treatment with ranitidine, it is necessary to exclude the possibility of a malignant disease of the esophagus, stomach or duodenum.

Contraindications to the use of ranitidine

Hypersensitivity to ranitidine or other components of the drug. Pregnancy, lactation. Children's age up to 14 years.

Side effects of ranitidine

From the nervous system and sensory organs: headache, feeling of fatigue, dizziness, drowsiness, insomnia, vertigo, anxiety, depression; rarely - confusion, hallucinations (especially in elderly and weakened patients), reversible blurred vision, impaired accommodation of the eye.
From the cardiovascular system and blood (hematopoiesis, hemostasis): arrhythmia, tachycardia, bradycardia, AV block, decreased blood pressure; reversible leukopenia, thrombocytopenia, granulocytopenia; rarely - agranulocytosis, pancytopenia, sometimes with bone marrow hypoplasia, aplastic anemia; sometimes - immune hemolytic anemia.
From the gastrointestinal tract: nausea, vomiting, constipation, diarrhea, abdominal discomfort, pain; rarely - pancreatitis. Sometimes - hepatocellular, cholestatic or mixed hepatitis with/without jaundice (in such cases, ranitidine should be stopped immediately). These effects are usually reversible, but in rare cases they can be fatal. Rare cases of liver failure have also been reported. In healthy volunteers, AST concentrations were increased by at least 2-fold relative to pre-treatment levels in 6 of 12 people receiving 100 mg 4 times IV for 7 days and in 4 of 24 people receiving 50 mg 4 times IV for 5 days.
From the musculoskeletal system: rarely - arthralgia, myalgia.
Allergic reactions: skin rash, bronchospasm, fever, eosinophilia; rarely - erythema multiforme, anaphylactic shock, angioedema.

Ranitidine interactions

Antacids, sucralfate in high doses (2 g) slow down the absorption of ranitidine (when used simultaneously, the interval between taking antacids and ranitidine should be at least 1-2 hours).
Smoking reduces the effectiveness of ranitidine. Additional prolongation of PT has been reported when ranitidine was coadministered with warfarin; however, in human pharmacokinetic studies at a ranitidine dose of 400 mg/day, no interaction was observed; ranitidine had no effect on the clearance of warfarin and PT; the possibility of interaction with warfarin at doses above 400 mg per day has not been studied. When administered twice daily with ranitidine and triazolam, plasma concentrations of triazolam were higher than when administered with triazolam alone. Triazolam AUC values in people 18–60 years of age were 10 and 28% higher after administration of ranitidine 75 and 150 mg tablets than after administration of triazolam alone. In patients over 60 years of age, AUC values were approximately 30% higher after taking ranitidine 75 and 150 mg tablets. Ranitidine increases the AUC (by 80%) and concentration (by 50%) of metoprolol in the blood serum, while the half-life of metoprolol increases from 4.4 to 6.5 hours. Reduces the absorption of itraconazole and ketoconazole (ranitidine should be taken 2 hours after taking them). Inhibits the metabolism of phenazone, hexobarbital, glipizide, buformin, BCC. Compatible with 0.9% sodium chloride solution, 5% dextrose solution, 0.18% sodium chloride solution and 4% dextrose solution, 4.2% sodium bicarbonate solution. When taken simultaneously with drugs that depress bone marrow, the risk of developing neutropenia increases. Possible interaction with alcohol. When taken together with loperamide, serious heart problems are possible (FDA Notice dated 6.7.2916).

Ranitidine overdose

Symptoms: convulsions, bradycardia, ventricular arrhythmias.
Treatment: induction of vomiting or gastric lavage, symptomatic therapy. For convulsions - intravenous diazepam, for bradycardia - atropine, for ventricular arrhythmias - lidocaine.

Use of ranitidine during pregnancy and lactation

Ranitidine is contraindicated for use during lactation. FDA category of risk for the fetus when used throughout pregnancy is B (animal studies have not revealed a risk of adverse effects on the fetus; there have been no adequate studies in pregnant women).

general information

By Decree of the Government of the Russian Federation of December 30, 2009 No. 2135-r, ranitidine (solution for intravenous and intramuscular administration; solution for injection; film-coated tablets; film-coated tablets) is included in the List of vital and essential medicines.

Trade names of drugs containing the active ingredient ranitidine

Having or having been registered in Russia: Asitek, Acidex, Atsilok, Vero-Ranitidine, Gistak, Zantac, Zantin, Zoran, Raniberl 150, Ranigast, Ranisan, Ranison, Ranitidine, Ranitidine-LekT, Ranitidine Vramed, Ranitidine SEDICO, Ranitidine-AKOS, Ranitidine-Acri, Ranitidine-BMS, Ranitidine-ratiopharm, Ranitidine-Ferein, Ranitidine hydrochloride, Ranitidine film-coated tablets, Ranitin, Rantag, Rantak, Ranks, Ulkodin, Ulran, Yazitin from the following manufacturers: Akrikhin HFC, Russia;
Bryntsalov-A, Russia; Wave International, India; Vector, Russia; Vector-Farm, Russia; Vertex, Russia; J.R. Sharma Overseas, India; Health UKR, Ukraine; Irbit Chemical and Pharmaceutical Plant, Russia; Kanonpharma production, Russia; Krka, Slovenia; Moskhimfarm-preparations named after. ON THE. Semashko, Russia; Natur Product, France; Natur Product Europe B.V., the Netherlands; Ozon, Russia; Olainfarm, Latvia; Panacea Biotech, India; Northern Star, Russia; Serena Pharma/Shreya Life Sciences, India; HEMOPHARM CONCERN A.D., Yugoslavia. The Zantac brand of ranitidine is registered in the USA: prescription Zantac 150 USP, Zantac 300 USP, Zantac 25 EFFERdose, Zantac Syrup USP and over-the-counter Zantac 75, which has a reduced content of ranitidine - 75 mg and is approved for self-treatment of heartburn.

Instructions from manufacturers

Some instructions for the medical use of drugs with the only active ingredient - ranitidine (pdf):

For Russia:
"Ranitidine-Akri", film-coated tablets, 150 mg, JSC "Akrikhin",

for USA (in English):

"Zantac 150 (ranitidine hydrochloride) Tablets, USP. Zantac 300 (ranitidine hydrochloride) Tablets, USP. Zantac 25 (ranitidine hydrochloride effervescent) EFFERdose Tablets, USP. Zantac (ranitidine hydrochloride) Syrup, USP. Prescribing Information". GlaxoSmithKline, January 2011

Ranitidine has contraindications, side effects and application features; consultation with a specialist is necessary. Back to section

Side effects

Hematopoietic system:

leukopenia (with long-term therapy);
thrombocytopenia.

The cardiovascular system:

development of atrioventricular block (rarely, mainly with intravenous infusion).

Digestive tract:

stool disorders ( constipation / diarrhea syndrome );
hepatitis (extremely rare).

Side effects from the central nervous system:

vertigo , dizziness ;
fast fatiguability;
blurred visual perception;
headache;
hallucinations (extremely rare);
confusion (extremely rare).

Endocrine system, metabolism:

increased prolactin ;
increased creatinine ;
amenorrhea;
gynecomastia;
decreased libido ;
impotence.

Other reactions:

recurrent mumps ;
arterial hypotension;
bronchospasm;
arthralgia;
hair loss;
anaphylactic shock;
angioedema;
hives;
various rashes on the skin;
myalgia.

Side effects of the drug Ranitidine

Transient changes in liver function tests are possible; isolated cases of hepatitis (hepatocellular, cholestatic or mixed), usually reversible, accompanied or not accompanied by jaundice. Rare cases of acute pancreatitis have been described. From the hematopoietic system: rarely - reversible leukopenia, thrombocytopenia; isolated cases of agranulocytosis or pancytopenia, sometimes with bone marrow hypoplasia or aplasia. Allergic reactions: rarely - skin rash, urticaria, angioedema, anaphylactic shock, bronchospasm, arterial hypotension. From the cardiovascular system: rarely - bradycardia, AV block, asystole (with injection). From the central nervous system and sensory organs: rarely - headache, sometimes severe, dizziness; very rarely - reversible confusion and hallucinations, mainly in seriously ill and elderly patients; Some cases of the development of blurred visual perception, apparently caused by a violation of accommodation, have been described. From the endocrine status: very rarely - engorgement or discomfort in the mammary glands in men. Other side effects are rarely observed: arthralgia and myalgia.

Ranitidine tablets, instructions for use (Method and dosage)

The treatment regimen is selected individually. The tablets are intended to be taken orally.

Daily dosage is 300-450 mg (can be increased to 600-900 mg if necessary), divided into 2-3 doses. To prevent exacerbation of diseases of the digestive tract, the drug is prescribed at bedtime at a dose of 150 mg. The duration of therapy is determined by the dynamics of the disease.

For pathology of the renal system, the medication is prescribed twice a day at a dose of 75 mg. Instructions for use of Ranitidine Akos are similar. Your doctor will tell you how long you can take the pills (on average, the course of treatment is 2-4 weeks).

Use of the drug Ranitidine

Adults are administered intravenously slowly (at least 2 minutes) at a dose of 50 mg (in a volume of 20 ml), if necessary, repeated injections are carried out every 6–8 hours; IV drip at a rate of 25 mg/hour for 2 hours, if necessary, repeated administration after 6–8 hours. IM is prescribed at a dose of 50 mg (2 ml) every 6–8 hours. To prevent bleeding from stress ulcers in seriously ill patients or for the prevention of recurrent bleeding in patients with peptic ulcers of the stomach and duodenum, it is prescribed parenterally for the period when the patient cannot eat on his own. Patients with a continuing risk of bleeding may continue to take oral ranitidine 150 mg twice daily. For the prevention of bleeding from the upper gastrointestinal tract in seriously ill patients with stress ulcers, a slow IV administration of an initial dose of 50 mg followed by a continuous IV infusion of 0.125–0.25 mg/kg per hour is preferable. For patients at risk of developing acid aspiration, ranitidine is prescribed at a dose of 50 mg IM or IV slowly 45–60 minutes before general anesthesia. Orally, for active peptic ulcers of the stomach or duodenum, adults are prescribed 150 mg 2 times a day or 300 mg at night. In most cases, duodenal ulcers and benign gastric ulcers heal within 4 weeks. In some cases, scarring occurs later as treatment continues for the next 4 weeks. In the treatment of peptic ulcer of the duodenum, a dose of 300 mg 2 times a day is more effective than a dose of 150 mg 2 times a day and 300 mg at night. For anti-relapse treatment, 150 mg is prescribed at night; For patients who smoke, the dose is increased to 300 mg at night. When treating ulcers associated with taking NSAIDs, prescribe 150 mg 2 times a day or 300 mg at night for 8–12 weeks. For prophylactic purposes, when taking NSAIDs, 150 mg is prescribed 2 times a day. When treating postoperative stress ulcers, 150 mg is prescribed 2 times a day, usually for 4 weeks. Ulcers that do not heal within the specified period usually heal with continued treatment over the next 4 weeks. For reflux esophagitis, 150 mg 2 times a day or 300 mg at night is prescribed for 8 weeks; if necessary, the course of treatment can be extended to 12 weeks. For reflux esophagitis of II and III severity, the dose can be increased to 150 mg 4 times a day for 12 weeks. Long-term preventive therapy for reflux esophagitis - 150 mg 2 times a day. To eliminate pain from gastroesophageal reflux, 150 mg is prescribed 2 times a day for 2 weeks. If there is insufficient effectiveness, treatment can be continued at the same dose over the next 2 weeks. For Zollinger-Ellison syndrome, the initial dose is 150 mg 3 times a day; if necessary, the dose can be increased. Doses up to 6 g/day are usually well tolerated. For dyspepsia, 150 mg is prescribed 2 times a day for 6 weeks. If there is no positive effect from treatment, or if the condition worsens during treatment, a thorough examination of the patient should be carried out. To prevent bleeding from stress ulcers in seriously ill patients, as well as to prevent recurrent bleeding in patients with erosions, parenteral use of ranitidine can be replaced by oral administration at a dose of 150 mg 2 times a day, as soon as the patient is able to eat independently. To prevent the development of Mendelssohn's syndrome, a dose of 150 mg is prescribed orally 2 hours before anesthesia, and also (preferably) 150 mg the night before. During childbirth, women are prescribed 150 mg every 6 hours. For the treatment of peptic ulcers in children, the recommended dose of ranitidine is from 2 mg/kg to 4 mg/kg 2 times a day; the maximum daily dose is 300 mg.

Overdose

Main manifestations:

skin rashes;
confusion;
headache;
dizziness;
increased drowsiness.

First aid consists of taking enterosorbents ( Polysorb , Smecta , Activated Carbon and others), calling an ambulance.

Interaction

There is a decrease in ranitidine absorption rates when treated with antacids . Elderly patients experience deterioration in attention and memory while taking anticholinergic drugs . It is assumed that medications that block histamine H2 receptors are able to suppress the ulcerogenic effect of drugs from the NSAID on the gastric mucosa. There is a decrease in the clearance of Warfarin during treatment with Ranitidine. Medical practice describes a case of bleeding and hypoprothrombinemia in a patient who was taking Warfarin .

There may be an undesirable increase in the absorption rates of ranitidine during simultaneous therapy with bismuth tripotassium dicitrate . Cases of hypoglycemia when taking Glibenclamide .

Ranitidine inhibits the absorption of Itraconazole and Ketoconazole . The half-life of Metoprolol and its AUC increase during treatment with Ranitidine. The absorption of the drug changes when taking high doses of Sucralfate (more than 2 g).

There is a slowdown in the excretion of Procainamide through the renal system, which leads to an increase in the concentration of the active substance in the blood. The absorption of Triazolam increases, which is associated with a change in the pH of gastric juice. The risk of toxicity increases with treatment with Phenytoin , which is explained by a significant increase in its concentration in the blood. There is an increase in the bioavailability of Furosemide with simultaneous therapy with Ranitidine.

In the medical literature there is a description of a case of the development of ventricular arrhythmia of the bigeminy in a patient who took Ranitidine and Quinidine . When treated with Cisapride, of cardiotoxicity increases . There is an increase in the level of Cyclosporine in the blood with parallel treatment with Ranitidine.

Drug interactions Ranitidine

With the simultaneous use of ranitidine with sucralfate in high doses (2 g), the absorption of ranitidine may be impaired, so the interval between their administration should be at least 2 hours. Ranitidine does not suppress the activity of the liver enzyme system associated with cytochrome P450, so it does not potentiate the effect of drugs, metabolized with the participation of this system (diazepam, lidocaine, phenytoin, propranolol, theophylline, warfarin). Increases the AUC and increases the concentration of metoprolol in the blood serum (by 80 and 50%, respectively), while the half-life of metoprolol increases. Reduces the absorption of itraconazole and ketoconazole.

List of pharmacies where you can buy Ranitidine:

Moscow
Saint Petersburg

special instructions

In case of severe pathology of the renal system, the medication is prescribed with caution. Before using the drug, it is necessary to exclude oncological diseases of the intestines , esophagus and stomach .

Long-term therapy of weakened patients who are in a state of stress can provoke the development of bacterial disease of the stomach, as well as the subsequent spread of the inflammatory process.

If the medication is abruptly discontinued, the risk of relapse of peptic ulcer increases. Preventive therapy is more effective with a course of taking the drug for 45 days in the fall and spring, compared to continuous use.

In patients suffering from various rhythm disorders, rapid intravenous administration of the solution can provoke bradycardia . For persons with of porphyria , Ranitidine is prescribed with caution due to the risk of developing an acute attack.

Distortion of laboratory test parameters (liver enzymes, creatinine, GGT) is allowed. The time interval between taking antacids and Ranitidine should be at least 1-2 hours due to the risk of changes in the absorption of the active substance. Clinical studies confirming the safety of the drug in pediatric practice are limited.

Note!

The description of the drug Ranitidine on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.

Ranitidine analogs

Level 4 ATC code matches:
Gastrosidine

Gistak

Acylok

Cimetidine

Zantac

Kvamatel

Famotidine

Structural analogues:

Zantac;
Gistak;
Acylok;
Ranisan.

Reviews of Ranitidine

The drug allows you to quickly relieve pain in the epigastric region due to ulcerative pathology of the digestive tract, gastropathy by reducing the acidity of gastric juice. Reviews about Ranitidine are mostly positive, because... The drug is well tolerated, causing virtually no negative symptoms if the dosage regimen is followed. Among the advantages are the low cost of the tablets and the quick effect in relieving heartburn.

The medication can be used in emergency cases in case of errors in the diet to prevent exacerbation of gastritis and peptic ulcers.

The downside is that it is impossible to use the medication during pregnancy and lactation.

Ranitidine price, where to buy

The cost of tablets varies depending on the region of sale and pharmacy chain. The average price of Ranitidine in Russia is 30 rubles.

Online pharmacies in RussiaRussia
Online pharmacies in UkraineUkraine
Online pharmacies in KazakhstanKazakhstan

LuxPharma* special offer

Ranitidine TEVA (Zantac) tablet 300 mg 30 pcs
RUB 1,580 order
Zantac ampoules (Ranitidine in ampoules, Zantac) injection solution 25 mg/ml 2 ml No. 5
1970 rub. order

Pharmacy24

Ranitidine 150 mg N30 tablets PrAT "Tekhnolog", Uman, Cherkasy region, Ukraine
18 UAH. order
Ranitidine 150 mg N20 tablets PrAT "Technolog", Uman, Cherkasy region, Ukraine
12 UAH order
Ranitidine-Darnitsa 0.15g No. 10 tablets PrAT” Pharmaceutical company “Darnitsa”, Ukraine
8 UAH order
Ranitidine-Darnitsa 0.15g N20 tablets PrAT” Pharmaceutical company “Darnitsa”, Ukraine
15 UAH order

PaniPharmacy

Ranitidine tablets Ranitidine tablets 150 mg No. 20 Ukraine, Tekhnolog ChAO
13 UAH order
Ranitidine tablets Ranitidine-Zdorovye Forte tablets. p/o 300 mg No. 20 Ukraine, Health LLC
28 UAH order
Ranitidine tablets Ranitidine-Zdorovye Forte tablets. p/o 300 mg No. 10 Ukraine, Health LLC
15 UAH order
Ranitidine tablets Ranitidine tablets. p/o 0.15g No. 20 Ukraine, Darnitsa ChAO
19 UAH order
Ranitidine tablets Ranitidine tablets. p/o 0.15g No. 10 Ukraine, Health LLC
8 UAH order